United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $2.57, $0.82 better than the analyst estimate of $1.75. Revenue for the quarter came in at $322.8 million versus the consensus estimate of $308.04 million.

"Our continued growth shows that our medicines are reaching increasing numbers of patients suffering from pulmonary arterial hypertension (PAH)," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The commercial launch this quarter of our extended-release tablet called Orenitram® harkens an opportunity to bring prostacyclin-based medicine to more PAH patients in the U.S. than ever before, by providing a less-invasive route of administration than our prostacyclin infusion therapy called Remodulin®."

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.